| Benjamin Vogel, MD | |
|
148 W River St Ste 8, Providence, RI 02904-2615 | |
| (401) 606-3000 | |
| (401) 331-8110 |
| Full Name | Benjamin Vogel |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 56 Years |
| Location | 148 W River St Ste 8, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164522405 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD04526 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Miriam Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
News Archive
A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, "Enhanced antibody half-life improves in vivo activity" demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.
Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.
The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.
Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.
› Verified 4 days ago
| Entity Name | Affinity Physicians Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184944662 PECOS PAC ID: 0244413391 Enrollment ID: O20110326000053 |
News Archive
A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, "Enhanced antibody half-life improves in vivo activity" demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.
Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.
The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.
Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.
› Verified 4 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, "Enhanced antibody half-life improves in vivo activity" demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.
Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.
The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.
Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin Vogel, MD 117 Ellenfield St Ste 11c, Providence, RI 02905-4513 Ph: (401) 444-6779 | Benjamin Vogel, MD 148 W River St Ste 8, Providence, RI 02904-2615 Ph: (401) 606-3000 |
News Archive
A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, "Enhanced antibody half-life improves in vivo activity" demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.
Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.
The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.
Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.
› Verified 4 days ago
Donald Ramos, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 695 Eddy St, Providence, RI 02903 Phone: 401-272-1550 Fax: 401-421-8792 | |
Brittany S Hampton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1100 | |
Dr. Jane R. Sharp, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 297 Promenade St, Providence, RI 02908 Phone: 401-490-6464 | |
Dr. Katharine D Wenstrom, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 101 Dudley Street, 3rd Floor, Women & Infants Hospital Of Rhode Island/mfm Division, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7622 | |
Rebecca Crichton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 | |
Heather A Smith, MD, MPH Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 | |
Meena Theva, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 |